

# **Personal Genomics**

## **CDC Genomics Translation Agenda**

**Ralph J. Coates, PhD**

**Associate Director for Science**

**National Office of Public Health Genomics, NCCDPHP  
Centers for Disease Control and Prevention (CDC)**

**December 18, 2008, Bethesda, MD**



# Outline

**Context for the Translation Agenda**

**Clinical Utility of Family History**

**Extramural Translation Research**

**Extramural Translation Program**



**GAPPNet Initiative**



# Current translation to practice

## Rapid advances in research

→ Rapid translation into practice



Genetests.org; Primarily for single gene disorders

# **Translation of genetic testing in context of other health services in US**

**Healthcare Spending High, Exceeded Record \$2 Trillion in 2006. ~16% of GDP**

**U.S. behind many advanced countries in health**

**~55% of Americans receive recommended care for acute or chronic conditions, 50% receive recommended preventive care**

**~20%-30% receive contraindicated care**

**~30- 40% of dollars spent on overuse, underuse, misuse of services,etc.**

**Where does personal genomics fit?**

**U.S. Institute of Medicine: Building a Better Delivery System, 2005; NY Times, 1/8/2008; McGlynn NEJM 2003;248:2635; Shuster**

**Milbank Quarterly 2005; 83:243; Schroeder NEJM 2007;357:1221**



# What Consequences of Increasing Easy Availability of Genetic Testing?



The NEW ENGLAND JOURNAL of MEDICINE

Perspective JANUARY 10, 2008

## Letting the Genome out of the Bottle — Will We Get Our Wish?

David J. Hunter, M.B., B.S., Sc.D., M.P.H., Muin J. Khoury, M.D., Ph.D., and Jeffrey M. Drazen, M.D.

**I**t may happen soon. A patient, perhaps one you have known for years, who is overweight and

The test undergone by the patient described above is one of the products of this new knowledge.



www.nature.com/nature

Vol 456 | Issue no. 7218 | 6 November 2008

## nature

### My genome. So what?

Research is needed into the way individuals use their genomic information, and into protection from its abuse by others.

**EDITORIAL**

1 My genome. So what? 

**NEWS**

11 How to get the most from a gene test Erika Check Hayden

12 Genomics takes hold in Asia David Cyranoski

**NEWS FEATURES**

18 The case of the missing heritability Brendan Maher

23 Standard and pores



# **Unanswered Questions about Genetic Tests in Translation**

**How valid and reliable are the genetic tests & how well do they predict outcomes?**

**What are the benefits and harms (utility)?**


**What actions should be taken based on results?**

**How should the medical community, public health, policy makers respond?**



# CDC-Proposed Translation Research Continuum in Genetics


T0 = gene discovery



Continuum Adapted from Khoury Genet Med 2007;9:665; for related see: Woolf JAMA 2008;299:211; IOM Clinical Research Roundtable, Sung 2005



# Currently, Limited Research for Evaluation & Implementation



Khoury Genet Med 2007;9:665



# **Need for More Translation Research & Programs**


**“The past decade has seen a torrent of funding for basic research that dwarfs the funding for translational research and oversight of genetics and genomics. Consequently there is no capacity or infrastructure to meet the tsunami of basic research discoveries and move these discoveries rationally into clinical application.”**

**Hudson K. Health Affairs 2008;27(6):1612-5.**



# Genomic tests ready for use?

## Evaluation of Genomic Applications in Practice and Prevention



### Purpose:

Establish and test a systematic, evidence-based process for evaluating genetic tests and other applications of genomic technology in transition from research to practice

[www.egappreviews.org/](http://www.egappreviews.org/)  
[cdc.gov/genomics/gtesting/](http://cdc.gov/genomics/gtesting/)

# **EGAPP Products Help Guide Translation Research Agenda**

**Systematic evidence reviews evaluating  
analytic & clinical validity & clinical  
utility**


**Recommendations on appropriate use of  
genetic tests & other applications**

**Recommendations for research to fill  
specific evidence gaps**

[www.egappreviews.org/](http://www.egappreviews.org/)  
[cdc.gov/genomics/gtesting/](http://cdc.gov/genomics/gtesting/)



# Information at [www.egappreviews.org](http://www.egappreviews.org)



[Home](#)  
[About EGAPP](#)  
[Working Group](#) >  
[Topics](#)  
[Methods](#)  
[Evidence Reports](#)  
[Recommendations](#)  
[Other EGAPP Activities](#) >  
[Resources](#) >  
[Contact Us](#)



## What's New

EGAPP Working Group Releases F  
the December issue of *Genetics in*

- See the [Working Group anno](#)
- Read the [Genetics in Medicine press release](#).

## Evaluation of Genomic Applications in Practice and Prevention



Evaluation of Genomic Applications in Practice and Prevention (EGAPP) is an initiative launched in 2004 to support a coordinated, systematic process for evaluating public health practice in the United States.

The EGAPP Working Group was established to evaluate evidence regarding the validity and utility of rapidly emerging genetic tests. The Working Group develops methods and selects tests, reviews CDC-commissioned evidence, and provides guidance on appropriate use of genetic tests in specific clinical settings.



[Get email updates](#)

## About EGAPP

## EGAPP Working Group

## Topics

## Methods

## Evidence Reports

## Recommendations

# Outline

Context for the Research Agenda

**Clinical Utility of Family History**

Extramural Translation Research

Extramural Translation Program

GAPPNet Initiative



# **Family History & Genomics Contribute to Personalized Medicine**

## **Components of Personalized Medicine**

**Quality clinician-patient relationships**

**Informed patients, shared decisions**

**Personal medical & family health histories**

**Health habits evaluation, Preventive services**

**Current diagnostic, treatment technologies**

**Genomics, Health Information Technology**

**Combination → personalized health care**



# **Research Needed to Evaluate Clinical Utility of Family History & Genomics**

**Everyone has family history (FH)**

**FH risk factor for most diseases**

**FH risk ratios ~ = or > genetic variants**

**FH combines information on gene combinations, environment, behaviors**

**FH low cost “omics” tool (<\$1,000s)**

**Randomized clinical trials needed to evaluate clinical utility of both**



# CDC Supported Study Evaluating Clinical Utility of Family History

**Will the risk notification and tailored messages using a family history tool change behaviors?**

**use of clinical services  
lifestyle changes  
family communication**



# Family History Stratification & Intervention

## Data Collection

## Risk stratification

## Intervention

**Strong**

Personalized prevention recommendations & referral for further evaluation

**Moderate**

Personalized prevention recommendations

**Weak**

Reinforce standard prevention recommendations

**Family History Tool**



# Randomized Trial in Primary Care

**INTERVENTION**  
n=23 practices

Pretest

FH-risk assessment  
and messages

Posttest

6 months

**CONTROL**  
n=18 practices

Pretest

Generic  
messages

Posttest

FH-risk assessment  
and messages



# Outline

Context for the research agenda

Clinical utility of family history

**Extramural Translation Research**

Extramural Translation Program

GAPPNet Initiative



# CDC Translation Research

**Goal:** Support research needed for evidence-based clinical and public health practice in genomics

**Focus:** Fill Evidence Gaps identified by EGAPP & USPSTF reviews & recommendations



# Research Objectives

Evaluations of validity, utility, ELSI  
tests identified by EGAPP Working Group  
[egappreviews.org/workingrp/topics.htm](http://egappreviews.org/workingrp/topics.htm)

Effectiveness of interventions to increase use  
clinical practices recommended by the USPSTF  
for *BRCA* testing (use of family history &  
counseling & testing)  
[ahrq.gov/clinic/uspstf/uspsbrgen.htm](http://ahrq.gov/clinic/uspstf/uspsbrgen.htm)



# Research Objectives

Effectiveness of interventions to educate the public or providers about gaps in existing knowledge for tests and potential harms & benefits of tests for which an EGAPP review found insufficient evidence to support a recommendation

[egappreviews.org/workingrp/reports.htm](http://egappreviews.org/workingrp/reports.htm)

Clinical utility of family medical history tools



# Funded Project

D. Veenstra, U. WA.

Evaluate the clinical utility (improved health outcomes, value in clinical decision making) of:

Warfarin pharmacogenomics

Gene expression profiling for treatment of early stage breast cancer

Factor V Leiden testing for pregnant women with clotting or adverse pregnancy outcomes

Collaborative process with stakeholders



# Outline

Context for the research agenda

Clinical utility of family history

Extramural Translation Research

**Extramural Translation Program**

GAPPNet Initiative



# CDC Translation Program

**Goal: Promote evidence-based clinical and public health practice in genomics**

**Focus: EGAPP, USPSTF reviews, recommendations**

**Supported activities: education, policy, surveillance, evaluation**



# Funded Project: MI Public Health

J. Bach, Michigan Department of Community Health

Multi-faceted, state-wide comprehensive program

Surveillance, health education, & policy

Translation of USPSTF *BRCA* recommendations  
into practice

Translation of EGAPP recommendations on  
hereditary colorectal cancer into practice

Evaluate effectiveness in changing knowledge, test  
use, insurance coverage



# **Funded Project: Los Angeles, VA**

**M. Scheuner, Sepulveda Research**

**Implement multi-component for primary care  
clinicians within Department of Veterans  
Affairs Greater Los Angeles Healthcare System**

**For hereditary breast-ovarian cancer &  
hereditary nonpolyposis colorectal cancer**

**Following USPSTF & EGAPP recommendations**

**Evaluate: family history documentation, referral  
of patients for counseling & testing**



# Funded Projects: Pharmacists

G Kuo, University of California, San Diego

Educational program with the American Pharmacists Association, the American Society of Health-System Pharmacists, & the American Association of Colleges of Pharmacy

Increase pharmacists' awareness of current knowledge of validity & utility of pharmacogenomic tests, potential benefits & harms

Focus EGAPP-evaluated tests

Evaluate: education coverage, delivery, & cost



# Funded Projects: Oregon

K Bradley, Oregon Public Health Division

Cancer genomics surveillance program of State's adult population & healthcare providers

Monitor use of cancer-specific genomic tests & family history

Focus on tests identified by EGAPP & USPSTF related to breast, colorectal, & ovarian cancers

Evaluate: information completeness, quality & usefulness of information to others



# **Outline**

**Context for the research agenda**

**Clinical utility of family history**


**Extramural Translation Research**

**Extramural Translation Program**

**GAPPNet Initiative**



# Genomic Applications in Practice and Prevention Network (GAPPNet)



# **Need for More Translation Research, Evaluation & Programs in Genomics**

**Little or no research to guide translation to practice – 97% now in T0, T1**

**Almost no infrastructure to implement newest genomic services**

**Research, evidence reviews, & programs can benefit from information exchange (GAPPNet)**

**Khoury Genet Med 2007;9:665**

**Hudson K. Health Affairs 2008;27(6):1612-5.**



# **Personal Genomics CDC Genomics Translation Agenda**

**More information : Public Health Genomics  
[cdc.gov/genomics](http://cdc.gov/genomics)**

**Contact information: [RCoates@cdc.gov](mailto:RCoates@cdc.gov)**

**The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.**

